| 刘 雷,丁琛琛,胡 胜.非小细胞肺癌免疫功能与TKI治疗疗效的关系[J].中国肿瘤,2016,25(10):811-815. |
| 非小细胞肺癌免疫功能与TKI治疗疗效的关系 |
| Relationship Between Immune Function and Efficacy of EGFR-TKI Treatment in Advanced Non-small Cell Lung Cancer |
| 投稿时间：2015-10-15 |
| DOI：10.11735/j.issn.1004-0242.2016.10.A013 |
|
 |
| 中文关键词: 肺癌 免疫功能 酪氨酸激酶抑制剂 生存时间 |
| 英文关键词:lung cancer immune function EGFR-TKI overall survival |
| 基金项目: |
|
| 摘要点击次数: 1975 |
| 全文下载次数: 717 |
| 中文摘要: |
| 摘 要：［目的］ 研究晚期非小细胞肺癌(non-small cell lung cancer，NSCLC)患者表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors，EGFR-TKI)的疗效和毒性与宿主免疫功能的关系。［方法］ 95例Ⅳ期或复发NSCLC患者接受吉非替尼或厄洛替尼治疗，52例Ⅳ期或复发NSCLC患者接受含铂化疗，检测治疗前后患者免疫功能的变化，分析患者无进展生存期（progression-free-survival，PFS）、总生存时间（overall survival，OS）和副作用。［结果］ 经中位18个月的随访，吉非替尼或厄洛替尼治疗患者中，免疫功能正常或上调的患者中位PFS为9.3个月，稍长于免疫功能下降的患者（7.9个月），χ2=4.3，P=0.15。免疫功能正常或上调的患者中位OS为15.7个月，长于免疫功能下降组（15.7 vs 13.2个月，χ2=10.1，P=0.001）。［结论］ TKI治疗NSCLC患者，免疫功能上调和正常的患者OS明显延长，但与PFS没有关系。年轻可能是TKI治疗预后不好的危险因素。 |
| 英文摘要: |
| Abstract：［Purpose］ To evaluate the immune function in advanced NSCLC patients with EGFR-TKI treatment，investigating the relationship between immune function and treatment efficacy or toxicity. ［Methods］ A total of 95 cases with stage Ⅳ or recurrent NSCLC patients received tyrosine kinase inhibitors，and 52 cases with stage Ⅳ or recurrent NSCLC patients received chemotherapy. Immune function was detected before and after treatment，and survival and side effects were followed-up. ［Results］ After median follow-up of 18 months，gefitinib or erlotinib-treated patients，TKI therapy group with normal or better immune function，has a median PFS time of 9.3 months，which was moderately longer than those with weaker immune function with PFS time of 7.9 months，χ2= 4.3，P=0.15. Median overall survival in patients with better immune function was 15.7 months，which was longer than those with weaker immune function group (15.7 vs 13.2 months，χ2=10.1，P=0.001). ［Conclusion］ In NSCLC treated by TKI therapy，patients with normal or better immune function have significantly prolong overall survival，but not PFS. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |